Newsmeme!
Discover News you didn't know existed
Intron
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
Genome-Wide Screen Turns Up Primate-Specific Genes
Published July 3, 2009, 6:47 am, GenomeWeb News
NEW YORK (GenomeWeb News) – In a paper scheduled to appear online this week in the Proceedings of the National Academy of Sciences , researchers from the Genome Institute of Singapore and Wayne State University used a genome-wide screen to try to fish out primate-specific sequences in the human genome.
Biolex Therapeutics Announces Completion Of Enrollment In SELECT-2 Phase 2b Trial Of Locteron(R) In Chronic Hepatitis C
Published June 30, 2009, 3:09 am, Medical News Today
Biolex Therapeutics, Inc. announced that it has completed patient enrollment in the SELECT-2 Phase 2b trial of its lead product candidate Locteron® for the treatment of chronic hepatitis C.
OctoPlus' Licensee Biolex Completes Patient Enrollment in Phase IIb Study With Locteron
Published June 29, 2009, 8:53 am, Marketwire
LEIDEN, THE NETHERLANDS--(Marketwire - June 29, 2009) - OctoPlus N.V. ("OctoPlus") (Euronext: OCTO) announces today that its licensee Biolex Therapeutics (see separate Biolex press release on www.biolex.com ) has completed patient enrollment in its SELECT-2 Phase IIb clinical study of Locteron®, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. ...
OctoPlus' licensee Biolex completes patient enrollment in Phase IIb study with Locteron
Published June 29, 2009, 8:49 am, Marketwire
LEIDEN, NETHERLANDS--(Marketwire - June 29, 2009) - OctoPlus N.V. ("OctoPlus") (Euronext: OCTO) announces today that its licensee Biolex Therapeutics (see separate Biolex press release on www.biolex.com ) has completed patient enrollment in its SELECT-2 Phase IIb clinical study of Locteron®, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. OctoPlus ...
Biolex Therapeutics Announces Completion of Enrollment in SELECT-2 Phase 2b Trial of Locteron(R) in Chronic Hepatitis C
Published June 29, 2009, 6:54 am, Marketwire
PITTSBORO, NC--(Marketwire - June 29, 2009) - Biolex Therapeutics, Inc. announced today that it has completed patient enrollment in the SELECT-2 Phase 2b trial of its lead product candidate Locteron® for the treatment of chronic hepatitis C. Locteron, controlled-release interferon alpha 2b, is designed to improve patient care by providing a more convenient once-every-two week dosing schedule and ...
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |